Tivic Health has received approval for the next phase of clinical research on its non-invasive cervical vagus nerve stimulation (ncVNS) approach. This collaboration with Feinstein Institutes aims to refine the stimulation parameters of the ncVNS technology.
Physiological measurements will guide device performance enhancements, including electrode positioning and waveform optimizations. The data will inform clinical trial designs and target specific patient populations.
The company has successfully completed Phase 1 studies on ncVNS and is exploring clinical applications with Fletcher Spaght.
The optimization study will be conducted by Feinstein Institute of Bioelectronic Medicine, led by Dr. Theodoros Zanos and Dr. Blake Gurfein, Tivic Health’s Chief Scientific Officer.
Precision optimization is crucial in non-invasive neurostimulation device development. The research team will advance the ncVNS technology from proof-of-concept to disease-specific validation in future clinical trials.
The global vagus nerve stimulation market is estimated to reach $21.3 billion by 2030, with a 10.6% CAGR. Tivic Health aims to become a market leader in bioelectronic medicine by providing personalized and effective non-invasive treatments.
Tivic Health is a health tech company that develops and commercializes bioelectronic medicine. It utilizes stimulation of various nerve structures to treat chronic health conditions.
Tivic Health’s ClearUP, an FDA-approved bioelectronic sinus device, offers a drug-free therapeutic solution with a proven safety profile.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
